MPD: Data set: Graham3

Graham JB, Swarts JL, Leist SR, Schäfer A, Menachery VD, Gralinski LE, Jeng S, Miller DR, Mooney MA, McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Heise MT, Baric RS, Lund JM. Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathog. 2021 Jan;17(1):e1009287. doi: 10.1371/journal.ppat.1009287. Epub 2021 Jan 29. PubMed 33513210 FullText

Graham3 downloads
• Download Graham3 project data set animal data, as uploaded
• Download Graham3 animal data matrix with factor-related expansion applied as necessary
• Download Graham3 strain means, SD, N, etc. one row per strain/sex/measure

Ontology terms mapped to Graham3 measures:

MA:0000141 spleen
MP:0004972 abnormal regulatory T cell number
MP:0006387 abnormal T cell number
MP:0008073 abnormal CD4-positive, alpha beta T cell number
MP:0008077 abnormal CD8-positive, alpha-beta T cell number
MP:0008713 abnormal cytokine level
VT:0004972 regulatory T cell quantity
VT:0006387 T cell quantity
VT:0008073 CD4-positive T cell quantity
VT:0008077 CD8-positive T cell quantity
VT:0008713 cytokine amount

Investigators	Jessica B Graham Fred Hutchinson Cancer Research Center, Seattle, WA Ralph S Baric University of North Carolina, Chapel Hill, NC Jennifer M Lund Fred Hutchinson Cancer Research Center, Seattle, WA
Participants	Swarts JL, Leist SR, Schäfer A, Menachery VD, Gralinski LE, Jeng S, Miller DR, Mooney MA, McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Heise MT
Contact	Jessica B Graham jgraham@fredhutch.org
Part of a series:	• Graham2 - SARS-CoV infection of females see Graham2 • Graham3 - Baseline T cell signatures in males (no infection) (this project) Graham3
Funding Provided By	NIH AI100625
Project type	Phenotype strain survey data set
MPD identifiers	Graham3 MPD:1059
Data changelog	No updates/corrections. Initial release date: 04/2021.
Formatted citation	Click above to copy-paste the entire citation for this MPD web page.

This study used a screen of genetically diverse mice (F1 hybrids of Collaborative Cross strains of mice (CC RIX)) infected with mouse-adapted SARS-CoV in combination with comprehensive pre-infection immunophenotyping to identify baseline circulating immune correlates of severe virologic and clinical outcomes upon SARS-CoV infection. Eight to ten week old female CC RIX mice were infected intranasally and monitored for death, weight loss, and lung viral loads (data from this part of the study are in Graham2). Age-matched, uninfected male CC RIX mice were used to assess baseline steady-state splenic T cell numbers (data from this part of the study are in this project, Graham3).

Experimental groups in this study:
• Baseline

Procedures conducted:

• immune cell quantification

Baseline splenic T cell subsets.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)
Graham3:9	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4+ T cells [%] CD4_pos_tot 113800	CC RIX	102	m	8-10wks	N=4

Graham3:10	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Foxp3+ (Treg) [%] Tregs 113801	CC RIX	102	m	8-10wks	N=4

Graham3:11	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD29+ [%] Treg_CD29_pos 113802	CC RIX	102	m	8-10wks	N=4

Graham3:12	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD44hi [%] Treg_CD44_hi 113803	CC RIX	102	m	8-10wks	N=4

Graham3:13	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD73+ [%] Treg_CD73_pos 113804	CC RIX	102	m	8-10wks	N=4

Graham3:14	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CTLA-4+ [%] Treg_CTLA4_pos 113805	CC RIX	102	m	8-10wks	N=4

Graham3:15	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CXCR3+ [%] Treg_CXCR3_pos 113806	CC RIX	102	m	8-10wks	N=4

Graham3:16	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are ICOS+ (inducible costimulator) [%] Treg_ICOS_pos 113807	CC RIX	102	m	8-10wks	N=4

Graham3:21	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells (memory precursor panel) [%] mp_CD3_pos 113812	CC RIX	92	m	8-10wks	N=4

Graham3:22	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ (memory precursor panel) [%] mp_CD3_pos_CD8_pos 113813	CC RIX	92	m	8-10wks	N=4

Graham3:23	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD44+ (memory precursor panel) [%] mp_CD8_pos_CD44_pos 113814	CC RIX	91	m	8-10wks	N=4

Graham3:24	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD62L- (memory precursor panel) [%] mp_CD8_pos_CD62L_neg 113815	CC RIX	76	m	8-10wks	N=3

Graham3:25	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are Ki67+ (memory precursor panel) [%] mp_CD8_pos_Ki67_pos 113816	CC RIX	92	m	8-10wks	N=4

Graham3:26	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ (memory precursor panel) [%] mp_CD3_pos_CD4_pos 113817	CC RIX	92	m	8-10wks	N=4

Graham3:27	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD44+ (memory precursor panel) [%] mp_CD4_pos_CD44_pos 113818	CC RIX	91	m	8-10wks	N=4

Graham3:28	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD62L- (memory precursor panel) [%] mp_CD4_pos_CD62L_neg 113819	CC RIX	73	m	8-10wks	N=3

Graham3:29	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Ki67+ (memory precursor panel) [%] mp_CD4_pos_Ki67_pos 113820	CC RIX	92	m	8-10wks	N=4

Graham3:34	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells (memory panel) [%] mem_CD3_pos 113825	CC RIX	68	m	8-10wks	N=3

Graham3:35	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ (memory panel) [%] mem_CD3_pos_CD8_pos 113826	CC RIX	68	m	8-10wks	N=3

Graham3:36	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD44+ (memory panel) [%] mem_CD8_pos_CD44_pos 113827	CC RIX	73	m	8-10wks	N=3

Graham3:37	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD62L- (memory panel) [%] mem_CD8_pos_CD62L_neg 113828	CC RIX	68	m	8-10wks	N=3

Graham3:38	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are Ki67+ (memory panel) [%] mem_CD8_pos_Ki67_pos 113829	CC RIX	73	m	8-10wks	N=3

Graham3:39	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ (memory panel) [%] mem_CD3_pos_CD4_pos 113830	CC RIX	68	m	8-10wks	N=3

Graham3:40	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD44+ (memory panel) [%] mem_CD4_pos_CD44_pos 113831	CC RIX	73	m	8-10wks	N=3

Graham3:41	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD62L- (memory panel) [%] mem_CD4_pos_CD62L_neg 113832	CC RIX	68	m	8-10wks	N=3

Graham3:42	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Ki67+ (memory panel) [%] mem_CD4_pos_Ki67_pos 113833	CC RIX	73	m	8-10wks	N=3

Graham3:47	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells following stimulation with anti-CD3 and anti CD28 [%] ics_CD3_pos 113838	CC RIX	102	m	8-10wks	N=4

Graham3:48	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ following stimulation with anti-CD3 and anti-CD28 [%] ics_CD3_pos_CD8_pos 113839	CC RIX	102	m	8-10wks	N=4

Graham3:49	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IL17_pos 113840	CC RIX	102	m	8-10wks	N=4

Graham3:50	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IGNg_pos 113841	CC RIX	102	m	8-10wks	N=4

Graham3:51	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ following stimulation with anti-CD3 and anti-CD28 [%] ics_CD3_pos_CD4_pos 113842	CC RIX	102	m	8-10wks	N=4

Graham3:52	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IL17_pos 113843	CC RIX	102	m	8-10wks	N=4

Graham3:53	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IFNg_pos 113844	CC RIX	102	m	8-10wks	N=4

Graham3:54	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Tbet+ (transcription factor) by intracellular staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_Tbet_pos 113845	CC RIX	92	m	8-10wks	N=4

Graham3: Baseline T cell immune phenotypes in males of 104 F1 hybrid lines of Collaborative Cross strains of mice (CC RIX) predict virologic and disease control upon SARS-CoV infection (2021)